BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 17597710)

  • 1. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
    Swen JJ; Wessels JA; Krabben A; Assendelft WJ; Guchelaar HJ
    Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
    Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
    Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
    Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
    Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
    Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
    Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study.
    Tranah GJ; Chan AT; Giovannucci E; Ma J; Fuchs C; Hunter DJ
    Mol Carcinog; 2005 Sep; 44(1):21-30. PubMed ID: 15924351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
    Thijssen HH; Ritzen B
    Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
    Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
    Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.